Beam Therapeutics Profit Margin

Beam Therapeutics (BEAM) currently reports a profit margin of -68.73% as of June 2026. That compares with -661.31% in the prior-year period — up 89.6% year over year. That is below the Healthcare sector average of 13.39%. Use the charts on this page to explore Beam Therapeutics's profit margin history and peer comparisons.

Beam Therapeutics's profit margin increased from -661.31% to -68.73% — a 89.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Beam Therapeutics's profit margin of -68.73% is lower than the Healthcare sector average of 13.39%. That is roughly 613.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Beam Therapeutics's current -68.73% should be judged against Healthcare norms (sector average: 13.39%) and against BEAM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -68.73%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.39%. From there, open related valuation or income-statement pages for Beam Therapeutics, and consider following BEAM for alerts when major investors trade the stock.